These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 194681)
1. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681 [TBL] [Abstract][Full Text] [Related]
2. Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Wells SA; Santen RJ; Lipton A; Haagensen DE; Ruby EJ; Harvey H; Dilley WG Ann Surg; 1978 May; 187(5):475-84. PubMed ID: 646874 [TBL] [Abstract][Full Text] [Related]
3. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633 [TBL] [Abstract][Full Text] [Related]
4. Aminoglutethimide in the treatment of advanced breast cancer. Stuart-Harris RC; Smith IE Cancer Treat Rev; 1984 Sep; 11(3):189-204. PubMed ID: 6241038 [No Abstract] [Full Text] [Related]
5. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen. Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338 [TBL] [Abstract][Full Text] [Related]
6. Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone. Santen RJ; Wells SA; Runić S; Gupta C; Kendall J; Rudy EB; Samojlik E J Clin Endocrinol Metab; 1977 Sep; 45(3):469-79. PubMed ID: 198423 [No Abstract] [Full Text] [Related]
7. Aminoglutethimide dose and hormone suppression in advanced breast cancer. Harris AL; Dowsett M; Jeffcoate SL; Smith IE Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901 [TBL] [Abstract][Full Text] [Related]
8. Medical adrenalectomy and plasma steroids in advanced breast carcinoma. Newsome HH; Brown PW; Terz JJ; Lawrence W Surgery; 1978 Jan; 83(1):83-9. PubMed ID: 619476 [TBL] [Abstract][Full Text] [Related]
9. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. Dowsett M; Harris AL; Smith IE; Jeffcoate SL J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629 [TBL] [Abstract][Full Text] [Related]
10. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Harris AL; Dowsett M; Smith IE; Jeffcoate S Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150 [TBL] [Abstract][Full Text] [Related]
11. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer. Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533 [TBL] [Abstract][Full Text] [Related]
12. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. Samojlik E; Santen RJ; Wells SA J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399 [No Abstract] [Full Text] [Related]
13. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050 [TBL] [Abstract][Full Text] [Related]
14. Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. Dowsett M; Mehta A; Cantwell BM; Harris AL Eur J Cancer; 1991; 27(7):846-9. PubMed ID: 1657077 [TBL] [Abstract][Full Text] [Related]
15. How effective is surgical adrenalectomy in lowering steroid hormone concentrations? Worgul TJ; Santen RJ; Samojlik E; Wells SA J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336 [TBL] [Abstract][Full Text] [Related]
16. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301 [TBL] [Abstract][Full Text] [Related]
17. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205 [TBL] [Abstract][Full Text] [Related]
18. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. Bruning PF; Bonfrer JM; Hart AA; van der Linden E; de Jong-Bakker M; Moolenaar AJ; Nooijen WJ Eur J Cancer Clin Oncol; 1989 Feb; 25(2):369-76. PubMed ID: 2702989 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. Coombes RC; Chilvers C; Dowsett M; Gazet JC; Ford HT; Bettelheim R; Gordon C; Smith IE; Zava D; Powles TJ Cancer Res; 1982 Aug; 42(8 Suppl):3415s-3419s. PubMed ID: 6211228 [TBL] [Abstract][Full Text] [Related]
20. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Harris AL; Dowsett M; Smith IE; Jeffcoate SL Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]